| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.84B | 26.14B | 24.45B | 21.55B | 17.48B | 13.78B |
| Gross Profit | 12.23B | 11.59B | 10.82B | 9.01B | 7.33B | 5.81B |
| EBITDA | 6.52B | 6.66B | 5.08B | 5.13B | 4.08B | 3.03B |
| Net Income | 3.56B | 3.30B | 3.27B | 2.78B | 2.39B | 1.67B |
Balance Sheet | ||||||
| Total Assets | 41.79B | 38.89B | 34.29B | 29.77B | 24.88B | 18.26B |
| Cash, Cash Equivalents and Short-Term Investments | 1.47B | 1.52B | 1.59B | 1.70B | 1.51B | 1.17B |
| Total Debt | 11.85B | 10.36B | 9.52B | 8.26B | 6.91B | 4.92B |
| Total Liabilities | 23.01B | 20.48B | 18.96B | 16.43B | 14.12B | 9.59B |
| Stockholders Equity | 18.64B | 18.26B | 15.21B | 13.24B | 10.64B | 8.61B |
Cash Flow | ||||||
| Free Cash Flow | 4.30B | 3.95B | 4.02B | 2.72B | 2.63B | 2.55B |
| Operating Cash Flow | 4.69B | 4.49B | 4.46B | 3.07B | 2.94B | 2.81B |
| Investing Cash Flow | -4.74B | -3.34B | -4.16B | -2.72B | -3.29B | -1.30B |
| Financing Cash Flow | -99.00M | -1.40B | -346.00M | -308.00M | 573.00M | -998.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $16.27B | 20.62 | 14.17% | 2.47% | 0.40% | 38.42% | |
69 Neutral | kr163.52B | 45.89 | 19.96% | 0.70% | 9.39% | 10.45% | |
69 Neutral | kr78.55B | 14.07 | 13.13% | 3.16% | -0.74% | 6.55% | |
66 Neutral | €8.46B | 35.27 | 14.16% | 1.89% | 9.65% | 19.40% | |
66 Neutral | kr24.03B | 13.81 | 14.28% | 3.75% | 2.58% | 19.07% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
48 Neutral | €8.71B | -120.30 | -3.67% | 1.26% | 4.65% | -136.09% |
Lifco AB has acquired DB Orthodontics Ltd, a UK-based company that produces and sells orthodontic materials to dental professionals globally. The acquisition, which will be consolidated into Lifco’s Dental business area in the fourth quarter of 2025, is not expected to significantly impact Lifco’s earnings or financial position this year.
Lifco AB’s Nomination Committee has proposed Anders Oscarsson for the Board of Directors, replacing Axel Wachtmeister, who will not seek re-election in 2026. Oscarsson’s extensive experience in equities and owner relations at AMF is expected to bring valuable insights to Lifco’s strategic direction, potentially impacting its operations and stakeholder relations positively.
Lifco AB has acquired a majority stake in HEGUtechnik GmbH, a German niche contract manufacturer specializing in electronic components for automation in harsh industrial environments. This acquisition, which will be consolidated into Lifco’s Business Area Systems Solutions, is not expected to significantly impact Lifco’s financials this year but strengthens its position in the contract manufacturing sector.
Lifco AB reported a 9.0% increase in net sales to SEK 20,717 million for the first nine months of 2025, driven by acquisitions and organic growth. The company consolidated 13 new businesses, enhancing its market position, and maintained a strong financial position with interest-bearing net debt at 1.3 times EBITDA, allowing for potential future acquisitions.
Lifco AB has announced the acquisition of a majority stake in Nobil Bio Ricerche, an Italian company specializing in customizing implant surfaces for dental manufacturers. This acquisition, set to be consolidated in Lifco’s Dental business area by the fourth quarter of 2025, is not expected to significantly impact Lifco’s financial performance for the current year. The move aligns with Lifco’s strategy of expanding its portfolio in niche markets, potentially enhancing its industry positioning and offering additional growth opportunities.
Lifco AB has announced the acquisition of a majority stake in Citodent Imaging B.V., a Dutch company specializing in software for managing X-ray and diagnostic imaging for dentists in Europe. The acquisition, which will be integrated into Lifco’s Dental business area by the third quarter of 2025, is not expected to significantly impact Lifco’s earnings or financial position for the current financial year.